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Background and purpose: Chloroquine (CLQ), an antimalarial drug, has a lysosomotropic effect associated with
increased radiationsensibility, which is mediated by the leakage of hydrolytic enzymes, increased apoptosis,
autophagy and increased oxidative stress in vitro. In this phase II study, we evaluated the efficacy and safety of
radiosensibilization using CLQ concomitant with 30 Gray (Gy) of whole-brain irradiation (WBI) to treat patients with
brain metastases (BM) from solid tumors.
Methods: Seventy-three eligible patients were randomized. Thirty-nine patients received WBI (30 Gy in 10 fractions
over 2 weeks) concomitant with 150 mg of CLQ for 4 weeks (the CLQ arm). Thirty-four patients received the same
schedule of WBI concomitant with a placebo for 4 weeks (the control arm). All the patients were evaluated for
quality of life (QoL) using the EORTC Quality of Life (QoL) Questionnaire (EORTC QLQ-C30) (Mexican version) before
beginning radiotherapy and one month later.
Results: The overall response rate (ORR) was 54% for the CLQ arm and 55% for the control arm (p=0.92). The
progression-free survival of brain metastases (BMPFS) rates at one year were 83.9% (95% CI 69.4-98.4) for the CLQ
arm and 55.1% (95% CI 33.6-77.6) for the control arm. Treatment with CLQ was independently associated with
increased BMPFS (RR 0.31,95% CI [0.1-0.9], p=0.046).The only factor that was independently associated with
increased overall survival (OS) was the presence of< 4 brain metastases (RR 1.9, 95% CI [1.12-3.3], p=0.017). WBI was
associated with improvements in cognitive and emotional function but also with worsened nausea in both patients
groups. No differences in QoL or toxicity were found between the study arms.
Conclusion: Treatment with CLQ plus WBI improved the control of BM (compared with the control arm) with no
increase in toxicity; however, CLQ did not improve the RR or OS. A phase III clinical trial is warranted to confirm
these findings.
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Brain metastases (BM) are the major neurological compli-
cation from cancer [1-3]. As many as 40% of adult patients
with disseminated cancer experience brain metastases [4].
The two major primary malignancies associated with BM
are lung and breast cancer [2,5]. With supportive care and
corticosteroid therapy, the median survival of cancer pa-
tients with BM is approximately 1-2 months [6]. There have
been many attempts to improve this outcome, including
the treatment of brain metastases with whole brain irradi-
ation (WBI) surgery, stereotactic radiosurgery or a combin-
ation of these methods.The result has been a median
survival time that ranges from 6.5 to 10 months [7,8].Differ-
ent primary tumor control treatment strategies could im-
prove the OS of these patients [9,10]. Combinations of WBI
and several chemotherapeutic agents, including halogen py-
rimidines, fluoropyrimidines, gemcitabine and platinum
compounds, have failed to produce the expected thera-
peutic benefits [11]. There have been inconclusive benefits
from the use of temozolomide as a radiosensitizer [12-14].
When used as an antimalarial drug, chloroquine
(CLQ) can cause alterations in cell function, affecting
lysosomal membranes (lysosomotropic action) and pro-
ducing DNA damage [15,16]. The lysosomotropic effect
increases the cancer sensitivity to radiation and recruits
diverse antitumor mechanisms that include p53-
dependent apoptotic activation and the inhibition of au-
tophagic protein degradation [17]. In tumoral cells, CLQ
increases oxidative stress, lysosomal accumulation, mito-
chondrial depolarization and caspase activation [18].
There is evidence that CLQ may also increase the oxida-
tive stress induced by radiotherapy [19]. In vitro studies
performed in glioma cells have demonstrated that the
anticancer efficacy of CLQ is mediated by the induction
of apoptosis and the inhibition of autophagy. A murine
melanoma model exhibited caloric restriction and inhib-
ition of autophagy after CLQ treatment [17,18]. Clinical
studies conducted in primary brain tumors have sug-
gested that CLQ may improve OS when CLQ is admin-
istered in addition to conventional therapy or as an
adjuvant to conventional surgery, chemotherapy or ra-
diosurgery [20,21].
The aim of this study was to evaluate the radiosensitizing
effect of CLQ combined with WBI in patients with brain
metastases from solid tumors.
Patients and methods
We conducted a prospective, double-blind, randomized,
phase II clinical trial at a single institution (Instituto
Nacional de Cancerolgía, México City).The Institutional
Ethics and Scientific Committees approved the study
protocol (008-033-OMI) (CD-449-08), and the study was
conducted according to the Declaration of Helsinki and
was registered in ClinicalTrials.gov (NCT01894633). Allthe patients provided fully informed consent to partici-
pate. The primary objective was overall response rate
(ORR) in brain metastases. The secondary objectives com-
prised toxicity, the progression free survival of brain me-
tastases (BMPFS), overall survival (OS), event-free survival
(EFS) (BMPFS or death) and quality of life.
Patients
Eligible patients were 18-80 years of age, had at least
one BM ≥ 1 cm upon MRI analysis, had a Karnofsky
performance status (KPS) ≥70 and were classified as
RTOG-RPA I or II. The laboratory requirements were
an absolute neutrophil count of >1500/mm3,a platelet
count ≥ 100,000/mm3,blood urea nitrogen ≤25 mg/dL,
serum creatinine ≤ 1.5 mg/dL,serum bilirubin ≤ 1.5 ml/
dL and alanine aminotransferase and aspartate amino-
transferase levels≤ 2 times the upper normal limit. Pa-
tients who were eligible for radiosurgery or stereotactic
radiotherapy (patients with three or less brain metasta-
ses, size up to 4 cm and primary tumor controlled) or
who had a history of previous brain radiotherapy were
excluded. The clinical evaluations included a complete
clinical history, a KPS assessment and physical and
neurological examinations.
Study design
Patients were randomly assigned (1:1) without stratified
by a random number table to receive CLQ plus WBI
(CLQ arm) or a placebo plus WBI (control arm). The in-
vestigators and patients were blinded for treatment
assigned groups (double blind) The patients in the CLQ
arm received 30 Gy of total brain radiotherapy in 10
daily fractions from Monday to Friday. Furthermore, the
CLQ arm received a daily single dose of 150 mg CLQ
po1 hour prior to the radiation treatment, beginning
during the first radiotherapy fraction and continuing for
28 days. WBI was applied with two parallel and oppos-
ing fields using a 1.25- or 6-Mv photon beam. The dose
was calculated in the midplane along the central axis.
The patients in the control arm received 30 Gy of
whole-brain irradiation in 10 daily fractions and an oral
matching placebo for 28 days. In addition, after the radi-
ation treatment and as indicated, patients received the
appropriate systemic treatment for their primary tumor
and/or for non-brain metastases. Brain metastasis pro-
gression was treated with cranial re-irradiation or radio-
surgery whenever possible.
Follow-up
The patients were evaluated every week during treat-
ment and then every month until they were lost to
follow-up or died. During treatment, the patients under-
went clinical evaluations and biochemical profiling. After
three months of follow-up, the patients were evaluated
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logical symptoms prior to 3 months were evaluated by
MRI and considered as patients with brain disease pro-
gression. Patients without neurological symptoms and
who died prior to getting MRI, they did not register as
brain diseases progression. A radiologist from our institu-
tion evaluated the brain MRIs in accordance with the
RECIST 1.1 criteria [22]. The radiologist performed the
evaluation in a blinded fashion. The overall response
(ORR) encompassed complete responses (CRs) and partial
responses (PRs).Non-response included stable disease
(SD) and progressive disease (PD). Adverse events were
evaluated every week during treatment (28 days) and were
graded according to the NCI Common Terminology Cri-
teria (NCI-CTCAE v3.0).The local Ethics Committee
recommended ophthalmologic evaluations due to the po-
tential side effects of CLQ; therefore, all the patients were
evaluated for visual accuracy and underwent two fundus
examinations by a certified ophthalmologist: one after the
CLQ treatment ended and another two months later.
The 30-item EORTC Quality of Life (QoL) Questionnaire
(EORTC QLQ-C30) version 3.0 (Mexican version) was
used in this trial [23]. The EORTC QLQ-C30 v3 consisted
of five multi-item functional scales, three symptom scales,
a global health status/QoL scale, and six single items. The
scores were transformed according to the instructions in
the EORTC QLQ-C30 v3 manual. The possible scores on
all the scales and single items ranged from 0 to 100 points.
Higher scores on the functional and global health status
QoL scales reflect better functioning. On the symptom
scales, higher scores indicate larger numbers of symptoms
or problems. The QoL questionnaires were completed
1 day before radiotherapy began and 1 month later.
Statistical analysis
The sample size was calculated with a two-sided test using
a type-I error probability of 0.05 and a power of 0.80.
Thirty-five patients were required for each treatment arm
to detect a difference of 0.30 in the ORR (according to the
results of previous studies with temozolomide vs placebo)
[12]. Intention-to-treat analyses were performed. The
ORR and other categorical variables were estimated with
the chi-squared test or Fisher’s exact test. Variables with
significant or borderline significant values (p < 0.01) were
included in a multivariate logistic regression analysis.
The BMPFS was measured from the treatment initi-
ation until the date of brain’s disease progression (deter-
mined clinically or by brain MRI). The overall survival
was measured on the date of death or the last follow-up
visit. Event-free survival (EFS) was defined as the BMPFS
or death, whichever occurred first. The survival variables
were estimated using the Kaplan-Meier method, and the
survival rates of the treatment arms were compared
using the log-rank test; the Breslow test was applied ifthe two survival curves crossed. Adjustments for poten-
tial confounding variables were performed with a Cox
proportional hazards regression model. QoL compari-
sons between the treatment arms were performed before
and after radiotherapy and were analyzed using the
Wilcoxon related samples test. Differences of≥10% on
the EORTC QLQ-C30 scale were considered clinically
significant. Statistical significance was determined as a
two-sided p-value ≤0.05.
A priori, we expected the following clinical character-
istics to have significant effects on treatment response:
gender, age (<55 or ≥55 years, based on the patients
media, performance status (Karnofsky Index), number of
metastases to the CNS (<4 or ≥ 4 metastases), histology
and the interval in months between the cancer diagnosis
and the appearance of brain metastases (at diagnosis or
during a recurrence). The outcomes are reported with
95% confidence intervals (CIs). The statistical calcula-
tions were performed with the SPSS version 17 software
package (SPSS, Inc., Chicago, IL, USA).
Results
From January 2011 to February 2012, 78 patients were
evaluated for participation in this clinical trial. Two pa-
tients did not meet the inclusion criteria. Among the 76
patients who were enrolled in the study, 40 were randomly
assigned to the CLQ arm and 36 were assigned to the
control arm. Three patients withdrew their consent, in-
cluding one in the CLQ arm two in the control arm. Ul-
timately, there were 39 patients in the CLQ arm 34
patients in the control arm. Seventeen patients in the
CLQ arm and fourteen in the control arm died before the
radiological evaluation. Only 22 patients from the CLQ
arm and 20 patients from the control arm were evaluated
with MRI during the third month after WBI. The follow-
up period ended in February 2013. The CONSORT dia-
gram for this study is presented in Figure 1.
The patients’ median age was 54 ±12 years. Among
the patients, 53 (72.6%) were women and 20 (27.4%)
were men. The two most common malignancies were
lung and breast cancers (74% and 20.5%, respectively),
and the other primary tumors observed were melanoma
(2.7%), kidney cancer (1.4%) and primary unknown
(1.4%). All the patients were in good PS, with a median
Karnofsky index of 80%. Ninety-six percent of the pa-
tients were classified as RTOG-RPA II. The brain metas-
tases were identified at the diagnosis of the primary
tumor in the 57% of the cases and as a recurrence or
progression in 42.5% of the patients. The median of
number of metastases was three (ranges 1 to 30), 50 pa-
tients (68.5%) had ≤ 4 metastases; 12 patients (16.4%)
had 5-8 metastases and 11 patients (15.1%) had ≥ 9 me-
tastases. The median size was 22.8 ± 13 mm. The main




























Table 1 Patient characteristics
Characteristic CLQ arm Control arm p§
n = 39 n = 34
Gender
Male 11(28.2%) 9 (14.7%)
Female 28 (71.8%) 25 (85.3%) 0.868
Age (median) 55.7 ± 13 52 ± 10.6
Range
<55 18 (46.1) 21 (61.8.8%) 0.182
≥55 21 (53.91.8%) 13 (38.2.2%)
KPS
<80 8 (20.5%) 6 (17.6%) 0.756
≥80 31 (79.5%) 28 (82.4%)
No. metastases
<4 28 (71.8%) 22 (64.7%) 0.564
≥4 11 (28.2%) 12 (35.3%)
Histology
NSCLC and others 33 (84.6%) 25 (73.54%) 0.242
Breast cancer 6 (15.4%) 9 (26.5%)
RPA
I 1 (2.5%) 2 (5.9%) 0.476
II 38 (97.5%) 32 (94.1%)
Time of brain metastasis
During primary tumor diagnosis 23 (58.9%) 19 (55.9%) 0.816
Recurrence or progression 16 (41.151.6%) 15 (44.1%)
Abbreviations: CLQ chloroquine, KPS Karnofsky performance score, NSCLC non-
small-cell-lung cancer, RPA recursive partitioning analysis, CHT chemotherapy.
§Person Chi square test.
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in any of the above characteristics.
Complete response, partial response, stable disease and
progression were observed in 4.9%, 48.8%, 43.9% and 2.4%
of the patients, respectively. None of the studied clinical
factors were associated with response. The relationship
between the overall response rate (ORR) and the clinical
factors are shown in Additional file 1. There were no dif-
ferences in the ORR between the arms (54% for WBI plus
CLQ vs. 55% for the control arm [ORR 1.08, 95% CI (0.3-
3.7), p =0.92]). Table 2 shows the radiological response
according to the RECIST criteria for both arms.
No toxicity (grade 4 or 5) was observed in either arm,
and there were no significant differences in toxicity be-
tween the arms. The most frequent side effects reported
in both arms were headache, dizziness, nausea, and
vomiting. Additional file 2 lists the incidences of adverse
events. The ophthalmologic follow-up revealed no evi-
dence of visual side effects.
The median follow-up time was 8.4 months (SD
9.4 months) for the overall study population. TheTable 2 Radiological response (RECIST criteria)
CLQ arm Controlarm p
n=22 % n=20 %
Complete 1 4.5 2 10 .915
Partial 11 50 9 47.3 .867
Stable disease 9 40.9 9 47.3 .678
Progressive disease 1 4.5 0 0 .347
Objective response 12 54 11 55 .902
Abbreviations: CLQ + WBI Cloroquine plus Whole-brain irradiation.
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CLQ arm did not reach the median BMPFS, whereas the
BMPFS of the control arm was 13.3 months (95% CI
6.3-20, p=0.008) (Figure 2A). The BMPFS at one year
was 83.9% (95% CI 69.4-98.4) for the CLQ group and
55.1% (95% CI 33.6-77.6) for the placebo group. The
univariate analysis showed that age, primary tumor type
and treatment were associated with BMPFS (Table 3).
The multivariate analysis showed that CLQ treatment
was the only factor significantly associated with better
BMPFS (RR: 0.31, 95% CI 0.1-0.9, p=0.046).
The median OS was 8.4 months (95% CI 4.8-12.1).
There was no difference in the OS between the treatment
arms. In the CLQ arm, the median OS was 10.2 months
(95% CI5.00-15.2), whereas the control arm median OS
was 7.42 months (CI 95 3.87-10.98, p= 0.839) (Figure 2B).
The univariate analysis demonstrated that gender and the
number of metastases were significantly associated withMonths
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Figure 2 Efficacy of Chloroquine. A. Progression Free Survival of Brain M
to brain disease progression.OS and showed a trend with PS. In the multivariate ana-
lysis, the only factor associated with increased OS was the
number of metastases (< 4 vs.> 4 metastases) (RR 1.9,95%
CI: 1.12 -3.3, p =0.017) (Table 4).
The median event (progression or death)-free survival
was 7.5 months (95% CI 5.3-9.7). There was no differ-
ence between the CLQ arm (7.5 months; 95% CI: 3.1-
11.8) and the control arm (7.4 months; 95% CI 6.1-8.8)
(p =0.126) (Figure 2C). The only factor associated with
EFS was the number of metastases. The median EFS was
10.1 months (95% CI 7.1-13.0) for the group with < 4
metastases, compared with 2.9 months (95% CI 1.1-4.8)
for the group with ≥ 4 metastases (p=0.04) (Additional
file 3). When we analyzed the death due to brain disease
progressive only, the median was 27.1 months (95% CI
21.8-32.4). Patients of CLQ arm do not reach median
and patients of control arm had a median of 24.6 months
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Table 3 Factors associated with progression-free survival in patients with brain metastases.
Factor Median
(months)
CI (95%) Univariate analysis RR CI (95%) Multivariate analysis
P§ P§
Gender
Male NA (11.3-22.9) 0.257
Female 19.6
Age (years)
<55 13.9 (8.8-19.1) <0.001 0.22 (0.046 - 1.07) 0.06
≥55 NA
KPS
<80 28.1 (13.9 - 42) 0.946
≥80 22.3 (12.3-32.3)
Number of metastases
<4 22.3 (11.3 - 33.2) 0.351
≥4 14.9 (1.9 - 27.9)
Histology
NSCLC and others NA (6.6 -11.0) <0.001 0.46 (0.13 – 1.7) 0.24
Breast cancer 8.8
Time of brain metastasis
During primary tumor diagnosis 22.3 (5.5 - 39) 0.089
During recurrence 19.6 (10.1 - 29)
Treatment
Control arm 13.2 (6.3 - 20.1) 0.001 0.31 (0.1 – 0.9) 0.046
CLQ arm NA
Abbreviations: SE standard error, KPS Karnofsky performance status, NSCLC non-small-cell lung cancer, CHT chemotherapy, CLQ chloroquine. §P log-rank test.
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emotional, cognitive and social scales exhibited clinically
significant changes (10-point differences) before and after
treatment with either CLQ or placebo. Only the cognitive
function scale demonstrated a statistically significant
change (p=0.05). There was also an increase in nausea
after treatment (Additional file 4). There is no increase in
adverse effects in CLQ arm compared with control arm.
(Additional file 2). There were no differences in QoL be-
tween the treatment arms (Additional file 5).
Discussion
Our results suggest that CLQ improves the local control
and PFS of patients with BM when it is used concur-
rently with WBI, and there is no impact on the ORR or
OS. This is the first study to evaluate CLQ for the treat-
ment of BM; however, a previous study showed that
CLQ treatment during radiation and chemotherapy im-
proved the OS of patients with glioblastoma multiforme
(GBM) compared with a placebo. In a prospective, con-
trolled, randomized trial, 18 patients with GBM under-
went standard treatment with surgery, chemotherapy,
and radiotherapy. Nine patients received an additional
150-mg dose of chloroquine daily beginning 1 day aftersurgery and continuing through the observation period.
Nine matched patients were included as controls. There
was a significantly longer survival in the chloroquine-
treated patients than in the controls (33 +/- 5 and 11 +/-
2 months, respectively [p < 0.0002]) [24]. The same au-
thors published a randomized, double-blind, placebo-
controlled trial in which 30 postsurgical patients were al-
located to receive a150-mg daily dose of CLQ or placebo
for twelve months beginning on the fifth day after surgery.
All the patients also received conventional chemotherapy
and radiotherapy. The median survival after surgery was
24 months for the CLQ-treated patients and 11 months
for the placebo group. Although no statistically significant
difference was observed, the rate of death among the pa-
tients receiving CLQ was approximately one-half that of
the patients receiving the placebo (hazard ratio, 0.52 [95%
CI, 0.21 to 1.26]; P = 0.139) [20].
There are some differences between our trial and the
above studies, particularly in the duration of CLQ treat-
ment. In our trial, CLQ was administered for four weeks;
for the first two weeks it was combined with WBI, and
for the next two weeks it was administered alone. In the
Sotelo et al. study, CLQ was administered for one year
and was combined with carmustine. This combination
Table 4 Factors associated with overall survival in patients with brain metastases
Factor Median
(months)
CI (95%) Univariate analysis RR CI (95%) Multivariate analysis
p§ p§
Gender
Male 6.9 (5.9 -8.1) 0.05 0.65 (0.37 -1.3) 0.129
Female 11.3 (4.4 -18.1)
Age
<55 8.2 (4.3 -12.1) 0.44
≥55 8.4 (3.5 -13.4)
KPS
<80 5.1 (0 - 10.4) 0.1 0.8 (0.48 -1.3) 0.38
≥80 12.4 (4.9 -19.9)
Number of metastases
<4 13.5 (9.6 -17.4) 0.002 1.9 (1.12 -3.3) 0.017
≥4 2.9 (1.1- 4.8)
Histology
NSCLC and others 7.9 (3.8 -11.9) 0.67
Breast cancer 4.5 (1.9 -17)
Time of brain metastasis
During primary tumor diagnosis 10.2 (4.3-16) 0.743
During recurrence 8.2 (3.9-12.5)
Treatment
Control arm 7.42 (3.8 -11) 0.637
CLQ arm 10.1 (4.9 -15.3)
Abbreviations: SE standard error, KPS Karnofsky performance status, NSCLC non-small-cell lung cancer, CHT chemotherapy, CLQ chloroquine. §P log-rank test.
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hancement of the antimutagenic action; this could be
the explanation for the better outcomes observed in that
study [20,21]. In an in vitro study of glioma cells, Reyes
et al. showed that a combination of carmustine and
quinacrine (an antimalarial drug) increased the antineo-
plastic effect initially obtained with carmustine alone. In
the long term, this combination led to a high percentage
of tumor remissions compared with cells treated with
carmustine alone (55 and 16%, respectively; p <0.01).
The authors postulated that quinacrine might prevent
carmustine resistance by reducing the extent of the pri-
mary DNA rearrangements that are responsible for the
appearance of mutant clones [24,25]. In our study, it was
not possible to continue the CLQ treatment for a longer
time because all the patients required different chemo-
therapies specific for their primary tumors.
In contrast to GBM patients who die because of local
progression, most of the patients with BM died from ex-
tracranial tumor progression. This finding may explain
why improving the BMPFS did not impact the OS; none-
theless, the local control of BM has great relevance for
quality of life.Certain intracellular mechanisms may explain the ef-
fect of CLQ as a radiosensitizer. CLQ affects lysosomal
membranes and activates several antitumoral actions,
such as p53-mediated apoptosis, oxidative stress, caspase
activation, and other actions that potentiate the toxic ef-
fects of radiation in tumoral cells [15-19]. In a serum-
deprived U251 glioblastoma line, CLQ rapidly killed
serum-starved cancer cells in vitro by an independent
autophagy mechanism. CLQ induced lysosomal accumu-
lation and oxidative stress, leading to mitochondrial
depolarization, caspase activation and mixed apoptotic/
necrotic cell death [18]. Recent studies have suggested
novel mechanisms of radiosensitizer-induced cell death
that involve stress by reactive oxygen species (ROS),
lysosomal membrane permeabilization (LMP) and au-
tophagy inhibition [19]. Tumor cells may use autophagy
as a means of surviving the metabolic stress encountered
during radiation or systemic therapy; therefore, autoph-
agy inhibition by CLQ may explain the radiosensitization
property of this drug. Autophagy inhibition is a conse-
quence of lysosomotropic effects (the blocking of lyso-
somal function, acidification and trafficking) and the
degradation of autophagosomes, some of which are also
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malarial drugs, CLQ and hydroxychloroquine, inhibited
the autophagy induced by p53mediated apoptosis and
augmented the anticancer activity of cyclophosphamide
in Myc-driven lymphoma [27,28]. The inhibition of au-
tophagy by chloroquine increased cell death in imatinib-
resistant, BCRABLpositive CML cell lines and enhanced
the effect of the HDAC inhibitor vorinostat [29-31].
Chloroquine and the antimalarial drug quinacrine sensi-
tized gastrointestinal stromal tumor cells toward treat-
ment with imatinib both in vitro and in vivo [32].
Eventhough that chloroquine demonstrated in experi-
mental models potential synergistic effect with radiation
therapy, response rates in our study were not superior to
placebo. Chloroquine could increase necrosis in meta-
static lesions, inhibiting autophagy [16-19,26] and no
downsize brain metastases according with RECIST cri-
teria, caused a lack of response in conventional imaging
methods such as MRI.
In our trial, CLQ did not increase WBI toxicity and
did not cause any visual effects when it was administered
concurrently with WBI or after WBI. This result is in
contrast to findings that other radiosensitizers may cause
hematological and gastrointestinal toxicity [11,33].
Many clinical trials of radiosensitizers, including
ionidamine, metronidazole, misonodazole, motexafin gado-
linium, BUdr, efaproxiral and thalidomide, have had the
goal of improving the outcomes of patients with BM, how-
ever, the results of these studies are controversial, and no
significant improvements in OS or PFS have been shown.
Viani et al. [34] recently conducted a meta-analysis of 8
RCTs with 2317 patients. The results demonstrated that
WBI combined with radiosensitizers did not produce a
meaningful improvement in overall survival compared with
WBI alone (OR = 1.03, 95% CI0.84-1.25, p = 0.77).
Previous phase II trials have also suggested that
temozolomide improves the local control of BM without
increasing toxicity (except lymphopenia) [12]. Potential
benefits of CLQ use instead of temozolomide for patients
with BM are the lower price and favorable safety profile of
CLQ. CLQ is a widely studied drug with a well-established
toxicity profile and a low risk of potential side effects, ex-
cept when used at higher doses and for longer periods to
treat malaria and autoimmune diseases. The classical ocu-
lar toxicity (retinopathy and macular degeneration) associ-
ated with CLQ treatment is not observed with the doses
of CLQ used to treat BM or GBM.
Our study had methodological limitations, including a
small sample size and the absence of neurocognitive
evaluations, which may limit our results. In conclusion,
treatment with CLQ concurrently with radiotherapy for
two weeks and alone for two weeks thereafter was well
tolerated and suggested an improved BMPFS .These re-
sults require confirmation in a phase 3 trial.Additional files
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